Photo of Slobodan Paessler

View Scopus Profile

Slobodan Paessler, DVM, PhD

Director, ABSL3 Laboratory & GNL ABSL3 Laboratory

  • 3016 Citations
  • 32 h-Index
20032020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

  • COVID-19

Fingerprint Dive into the research topics where Slobodan Paessler is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Targeting Protein Folding to Inhibit Corona Virus Replication

Paessler, S.

Aldeyra

7/7/20 → 12/31/20

Project: Other project

Testing COVID-19 Inactivation through Novel Air Filtering System

Paessler, S.

Medistar Corporation

5/12/20 → 9/30/20

Project: Other project

Tests to Immediately Assess Efficacy of BioLargo Technologies to Inactivate SarS-COV-2 (COVID-19)

Paessler, S.

BioLargo Inc

4/24/20 → 4/24/21

Project: Other project

Host targeted approach against COVID-19

Paessler, S.

PTC Therapeutics Incorporated

4/23/20 → 8/31/20

Project: Other project

siRNAs to combat COVID-19

Paessler, S.

Sirvir Ltd

4/10/20 → 12/30/20

Project: Other project

Research Output

Animal models of lassa fever

Sattler, R. A., Paessler, S., Ly, H. & Huang, C., Mar 2020, In : Pathogens. 9, 3, 197.

Research output: Contribution to journal › Review article

Open Access
    • 2 Scopus citations

    Antiviral activities of type I interferons to SARS-CoV-2 infection

    Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S. & Huang, C., Jul 2020, In : Antiviral research. 179, 104811.

    Research output: Contribution to journal › Article

    Open Access
    • 15 Scopus citations

    Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats

    Ezeomah, C., Cunningham, K. A., Stutz, S. J., Fox, R. G., Bukreyeva, N., Dineley, K. T., Paessler, S. & Cisneros, I. E., Jul 2020, In : Brain, Behavior, and Immunity. 87, p. 725-738 14 p.

    Research output: Contribution to journal › Article

    • 1 Scopus citations

    Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein

    Amanat, F., Duehr, J., Huang, C., Paessler, S., Tan, G. S. & Krammer, F., Feb 14 2020, In : Journal of virology. 94, 5

    Research output: Contribution to journal › Article

    • 1 Scopus citations

    The Glycoprotein of the Live-Attenuated Junin Virus Vaccine Strain Induces Endoplasmic Reticulum Stress and Forms Aggregates prior to Degradation in the Lysosome

    Manning, J. T., Yun, N. E., Seregin, A. V., Koma, T., Sattler, R. A., Ezeomah, C., Huang, C., de la Torre, J. C. & Paessler, S., Mar 31 2020, In : Journal of virology. 94, 8

    Research output: Contribution to journal › Article

    • Activities

    • 1 Types of External academic engagement - Membership of peer review panel or committee

    Virology B Study Section, Center for Scientific Review

    Slobodan Paessler (Member)

    Jul 1 2015 → Jun 30 2021

    Activity: Other activity types › Types of External academic engagement - Membership of peer review panel or committee

    Press / Media

    BioSig Technologies Adopts Stockholder Rights Agreement

    Slobodan Paessler, John Manning & Cheng Huang

    7/16/20 → 7/19/20

    2 items of Media coverage

    Press/Media: Expert Comment

    BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit Nasdaq:BSGM

    Slobodan Paessler, John Manning & Cheng Huang

    7/17/20 → 7/18/20

    27 items of Media coverage

    Press/Media: Expert Comment

    A ‘catch and kill’ filter to control coronavirus indoors

    Slobodan Paessler & William Lawrence

    7/15/20

    1 item of Media coverage

    Press/Media: Expert Comment

    GNL aids research on superheated air filter for COVID-19 decontamination

    Slobodan Paessler

    7/15/20

    1 item of Media coverage

    Press/Media: Expert Comment

    BioSig Technologies: Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites

    Slobodan Paessler, John Manning & Cheng Huang

    7/13/20

    1 item of Media coverage

    Press/Media: Expert Comment